115 filings
Page 5 of 6
6-K
wusvocu2z62x5j9
4 Jun 21
Current report (foreign)
4:31pm
6-K
56ynhb
2 Jun 21
CureVac Appoints Klaus Edvardsen as Chief Development Officer
7:02am
6-K
ikzg8 m6x737oy40
28 May 21
Current report (foreign)
4:31pm
6-K
e0lhfhiw0b owi
26 May 21
CureVac Announces Financial Results for the First Quarter of 2021 and Business Updates
7:01am
6-K
5y840 6qwr6jzlg
13 May 21
Current report (foreign)
7:58am
6-K
ymilut 53amuxukqw
19 Apr 21
Current report (foreign)
7:00am
6-K
hc7bjgm81lvh4aw
15 Apr 21
CureVac Announces Financial Results and Business Updates for the Fourth Quarter and Full-Year of 2020
8:58am
6-K
d21tw35s
23 Mar 21
Current report (foreign)
8:00am
6-K
furxgx
22 Mar 21
Current report (foreign)
8:26am
6-K
xmbqae7
4 Mar 21
CureVac and Novartis Sign Initial Agreement on Manufacturing of COVID-19 Vaccine Candidate, CVnCoV
7:01am
6-K
r2jth8udj 7gc8
12 Feb 21
Current report (foreign)
6:30am
6-K
ndx0qv aijpm
5 Feb 21
CureVac and UK Government to collaborate on development of vaccines against SARS-CoV-2 variants
7:00am
6-K
mc4a 4h456lhow
4 Feb 21
Current report (foreign)
7:10am
6-K
d27ini3jzpux4f
4 Feb 21
CureVac Announces Full Exercise of Underwriters’ Option to Purchase Additional Common Shares
7:00am
6-K
z4mqyp4e
3 Feb 21
Current report (foreign)
6:30am
6-K
8gh wcr8jo
2 Feb 21
CureVac Announces Closing of $450 million Follow-on Public Offering of Common Shares
7:00am
6-K
kb0lgp1c5h1470a8g f8
1 Feb 21
Current report (foreign)
8:03am
6-K
2k84s77
28 Jan 21
CureVac Announces Pricing of $450 million Follow-on Public Offering of Common Shares
6:30am
6-K
yt2ekztt
25 Jan 21
CureVac Announces Proposed Public Offering of Common Shares
4:22pm
6-K
5s2ejp
19 Jan 21
ADVANCE PURCHASE AGREEMENT (“APA”)1 for the development, production, advance purchase and supply of a COVID-19 vaccine for EU Member States
6:41am